Answers are grounded in this paper and cite their sources.
This systematic review and meta-analysis of ICI clinical trial results noted consistently larger ST-HRs vs Cox HRs for ICI therapy, with an LT-DP of approximately 10%. These results suggest that Cox HRs may not provide a full picture of survival outcomes when the risk reduction from treatment is not constant, which may aid in the decision-making process of oncologists and patients.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: